Genotype-specific neutralizing antibody titers against Japanese encephalitis virus genotypes 1 and 3 in horses immunized with a genotype 3 vaccine.
Abstract: Japanese encephalitis is one of the most important mosquito-borne and zoonotic diseases in Asia and the Pacific region. Although the dominant Japanese encephalitis virus (JEV) genotype has shifted from G3 to G1 in Korea since 1990, a G3 strain (Anyang 300) has been used in vaccines for horses for almost 40 years. This study aimed to investigate the seroconversion rates and geometric mean titers (GMTs) of virus-neutralizing antibodies (VNAs) against JEV G1 and G3 in horses immunized with the G3 vaccine. Methods: Serum samples of 1,231 horses immunized with the Anyang 300 vaccine were collected in 2018. VNA titers against JEV KV1899 (G1) and Anyang 300 (G3) were measured in all serum samples using the virus neutralization test. Titers were analyzed according to blood sampling time (prior to and following annual revaccination), age, and region. Results: Rates of VNA titer >10 were 45.1% and 77.8% for G1, and 49.1% and 82.9% for G3 in samples taken before and after revaccination, respectively. GMTs of genotype-specific VNAs against JEV G1 and G3 were 8.3 and 11.6 before revaccination and rose to 27.2 and 65.4 following revaccination. Overall sero-positivity did not significantly differ between genotypes, but GMTs significantly differed among genotypes and sampling times. No significant difference was found in GMTs among age groups or regions. Conclusions: Genotype-specific neutralizing antibody titers against JEV G1 and G3 differed significantly in horses immunized with the G3 vaccine. Antigenic differences between genotypes could reduce the vaccine's efficacy, requiring the development of a new vaccine.
© Korean Vaccine Society.
Publication Date: 2020-07-31 PubMed ID: 32864366PubMed Central: PMC7445317DOI: 10.7774/cevr.2020.9.2.102Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The study investigated the effectiveness of genotype 3 (G3) Japanese Encephalitis Virus (JEV) vaccine used in horses against the genotypes 1 (G1) and 3 (G3) of the virus. The results showed significant differences in the amounts of neutralizing antibodies against both genotypes, highlighting the possible need for a new vaccine due to antigenic differences between genotypes.
Introduction
- The researchers studied Japanese encephalitis, a serious disease mainly found in Asia and the Pacific regions, which is transmitted mainly through mosquitos and affects both animals and humans.
- Over the past three decades in Korea, the dominant genotype of the Japanese Encephalitis Virus (JEV) has shifted from G3 to G1. However, for nearly 40 years, a G3 vaccine (Anyang 300) has been used to immunize horses against this disease.
- The study aimed to understand the effectiveness of a G3 vaccine in producing virus-neutralizing antibodies (VNAs) against both G1 and G3 genotype viruses.
Methods
- The study analyzed serum samples from 1,231 horses who had been immunized with the Anyang 300 vaccine in 2018.
- The titers (measurable concentration) of VNAs against the two genotypes of JEV viruses were measured in all serum samples using a virus neutralization test.
- These measurements were then analyzed based on the time of sample collection (before or after annual revaccination), age of the horse, and region.
Results
- The percent of serum samples with VNA titers greater than 10 against the G1 genotype was 45.1% before revaccination and 77.8% after revaccination. For G3, these percentages were 49.1% and 82.9%, respectively.
- The Geometric Mean Titer (GMT), a type of average used for skewed data, of VNAs against both G1 and G3 genotypes were 8.3 and 11.6 before revaccination, and increased to 27.2 and 65.4 after revaccination.
- While there was no significant difference in the overall sero-positivity rate between genotypes, the study found that GMTs significantly varied between genotypes and times of sampling.
- The research demonstrated no significant difference in GMTs among different age groups or regions.
Conclusions
- Significant differences were identified in the titers of neutralizing antibodies against JEV G1 and G3 in horses immunized with a G3 vaccine.
- This could be due to antigenic differences between the two genotypes which might be reducing the effectiveness of the vaccine against G1 genotype.
- As a result, the research suggests there may be a need to develop a new vaccine to ensure better protection against both genotypes of the virus.
Cite This Article
APA
Kim HH, Yang DK, Ji M, Lee SK, Hyun BH.
(2020).
Genotype-specific neutralizing antibody titers against Japanese encephalitis virus genotypes 1 and 3 in horses immunized with a genotype 3 vaccine.
Clin Exp Vaccine Res, 9(2), 102-107.
https://doi.org/10.7774/cevr.2020.9.2.102 Publication
Researcher Affiliations
- Viral Disease Research Division, Animal and Plant Quarantine Agency, Gimcheon, Korea.
- Viral Disease Research Division, Animal and Plant Quarantine Agency, Gimcheon, Korea.
- Viral Disease Research Division, Animal and Plant Quarantine Agency, Gimcheon, Korea.
- Korea Racing Authority, Gwacheon, Korea.
- Viral Disease Research Division, Animal and Plant Quarantine Agency, Gimcheon, Korea.
Conflict of Interest Statement
No potential conflict of interest relevant to this article was reported.
References
This article includes 28 references
- Choe YJ, Taurel AF, Nealon J, Seo HS, Kim HS. Systematic review of seroepidemiological studies on Japanese encephalitis in the Republic of Korea.. Int J Infect Dis 2018 Feb;67:14-19.
- Chung YJ, Nam JH, Ban SJ, Cho HW. Antigenic and genetic analysis of Japanese encephalitis viruses isolated from Korea.. Am J Trop Med Hyg 1996 Jul;55(1):91-7.
- Dash AP, Bhatia R, Sunyoto T, Mourya DT. Emerging and re-emerging arboviral diseases in Southeast Asia.. J Vector Borne Dis 2013 Apr-Jun;50(2):77-84.
- Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis.. Emerg Infect Dis 2009 Jan;15(1):1-7.
- Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes.. Clin Infect Dis 2013 Jan;56(2):267-70.
- Fan YC, Chen JM, Chen YY, Lin JW, Chiou SS. Reduced neutralizing antibody titer against genotype I virus in swine immunized with a live-attenuated genotype III Japanese encephalitis virus vaccine.. Vet Microbiol 2013 May 3;163(3-4):248-56.
- Gould E, Pettersson J, Higgs S, Charrel R, de Lamballerie X. Emerging arboviruses: Why today?. One Health 2017 Dec;4:1-13.
- Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain.. Expert Rev Vaccines 2011 Mar;10(3):355-64.
- Jeoung HY, Yang SJ, Choi YK. Surveillance of encephalitis-causing arboviruses in horses in South Korea. J Equine Vet Sci 2016;37:11–16.
- Kang BK, Hwang JM, Moon H, Han SY, Kim JM, Yang DK, Park BK, Song D. Comparison of the antigenic relationship between Japanese encephalitis virus genotypes 1 and 3.. Clin Exp Vaccine Res 2016 Jan;5(1):26-30.
- Kurane I, Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains.. Vaccine 2000 May 26;18 Suppl 2:33-5.
- Ma SP, Yoshida Y, Makino Y, Tadano M, Ono T, Ogawa M. Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan.. Am J Trop Med Hyg 2003 Aug;69(2):151-4.
- Mackenzie JS, Johansen CA, Ritchie SA, van den Hurk AF, Hall RA. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia.. Curr Top Microbiol Immunol 2002;267:49-73.
- Mansfield KL, Hernández-Triana LM, Banyard AC, Fooks AR, Johnson N. Japanese encephalitis virus infection, diagnosis and control in domestic animals.. Vet Microbiol 2017 Mar;201:85-92.
- Misra UK, Kalita J. Overview: Japanese encephalitis.. Prog Neurobiol 2010 Jun;91(2):108-20.
- Nah JJ, Yang DK, Kim HH, Song JY. The present and future of veterinary vaccines for Japanese encephalitis in Korea.. Clin Exp Vaccine Res 2015 Jul;4(2):130-6.
- Nga PT, Parquet MDC, Cuong VD, Ma SP, Hasebe F, Inoue S, Makino Y, Takagi M, Nam VS, Morita K. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia.. J Gen Virol 2004 Jun;85(Pt 6):1625-1631.
- Nitatpattana N, Dubot-Pérès A, Gouilh MA, Souris M, Barbazan P, Yoksan S, de Lamballerie X, Gonzalez JP. Change in Japanese encephalitis virus distribution, Thailand.. Emerg Infect Dis 2008 Nov;14(11):1762-5.
- Partridge J, Ghimire P, Sedai T, Bista MB, Banerjee M. Endemic Japanese encephalitis in the Kathmandu valley, Nepal.. Am J Trop Med Hyg 2007 Dec;77(6):1146-9.
- Pfeffer M, Dobler G. Emergence of zoonotic arboviruses by animal trade and migration.. Parasit Vectors 2010 Apr 8;3(1):35.
- Singh Z, Agarwal VK. Japanese Encephalitis : Is Routine Immunization Required?. Med J Armed Forces India 2005 Oct;61(4):357-9.
- Sugiura T, Shimada K. Seroepizootiological survey of Japanese encephalitis virus and Getah virus in regional horse race tracks from 1991 to 1997 in Japan.. J Vet Med Sci 1999 Aug;61(8):877-81.
- Sunwoo JS, Jung KH, Lee ST, Lee SK, Chu K. Reemergence of Japanese Encephalitis in South Korea, 2010-2015.. Emerg Infect Dis 2016 Oct;22(10):1841-3.
- Wang HY, Takasaki T, Fu SH, Sun XH, Zhang HL, Wang ZX, Hao ZY, Zhang JK, Tang Q, Kotaki A, Tajima S, Liang XF, Yang WZ, Kurane I, Liang GD. Molecular epidemiological analysis of Japanese encephalitis virus in China.. J Gen Virol 2007 Mar;88(Pt 3):885-894.
- Yang DK, Kim BH, Kweon CH, Kwon JH, Lim SI, Han HR. Molecular characterization of full-length genome of Japanese encephalitis virus (KV1899) isolated from pigs in Korea.. J Vet Sci 2004 Sep;5(3):197-205.
- Yang DK, Kim BH, Kweon CH, Nah JJ, Kim HJ, Lee KW, Yang YJ, Mun KW. Serosurveillance for Japanese encephalitis, Akabane, and Aino viruses for Thoroughbred horses in Korea.. J Vet Sci 2008 Dec;9(4):381-5.
- Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines.. Hum Vaccin Immunother 2014;10(2):263-79.
- Yun SM, Cho JE, Ju YR, Kim SY, Ryou J, Han MG, Choi WY, Jeong YE. Molecular epidemiology of Japanese encephalitis virus circulating in South Korea, 1983-2005.. Virol J 2010 Jun 14;7:127.
Citations
This article has been cited 2 times.- Yeh JY. Evaluation of dogs (Canis familiaris) as an indicator of Japanese encephalitis (JE) outbreaks: A retrospective serological study in the Seoul metropolitan area around the 2010 resurgence of JE in the Republic of Korea.. One Health 2022 Dec;15:100459.
- Mackenzie JS, Williams DT, van den Hurk AF, Smith DW, Currie BJ. Japanese Encephalitis Virus: The Emergence of Genotype IV in Australia and Its Potential Endemicity.. Viruses 2022 Nov 9;14(11).
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
